Lynn Sosa, MD
Assistant Professor AdjunctDownloadHi-Res Photo
Cards
Additional Titles
Principal Investigator, Connecticut Emerging Infections Program
Assistant Clinical Professor of Epidemiology (Microbial Diseases)
Contact Info
Epidemiology of Microbial Diseases
410 Capitol Avenue MS #11 TUB
Hartford, CT 06134
United States
About
Copy Link
Titles
Assistant Professor Adjunct
Principal Investigator, Connecticut Emerging Infections Program; Assistant Clinical Professor of Epidemiology (Microbial Diseases)
Biography
Dr. Lynn Sosa received her medical degree from Harvard Medical School and completed a residency in internal medicine at Massachusetts General Hospital. She served in the Epidemic Intelligence Service with the Centers for Disease Control and Prevention from 2005-2007, assigned to the Connecticut Department of Public Health. Since October 2007, Dr. Sosa has been with the Connecticut Department of Public Health and currently serves as the Coordinator of the TB and STD Control Programs and the Deputy State Epidemiologist.
Last Updated on April 07, 2025.
Appointments
Epidemiology of Microbial Diseases
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Epidemic Intelligence Service Officer
- Centers for Disease Control and Prevention (2007)
- Resident
- Massachusetts General Hospital (2005)
- MD
- Harvard Medical School (2002)
- BS
- Loyola University Chicago, Biology (1998)
Research
Copy Link
Overview
Medical Research Interests
Sexually Transmitted Diseases; Tuberculosis
Public Health Interests
Respiratory Disease/Infections; Sexually-Transmitted Infections; Community Engagement; Emerging Infectious Diseases
Research at a Glance
Yale Co-Authors
Frequent collaborators of Lynn Sosa's published research.
Publications Timeline
A big-picture view of Lynn Sosa's research output by year.
AmberJean P. Hansen, MPH, CCRP
9Publications
509Citations
Publications
2025
589. Late Onset Invasive Group B Streptococcal Disease Outbreak in a Neonatal Intensive Care Unit Identified Through Whole Genome Sequencing — Connecticut, 2020–2024
Lambert M, Jones S, Mueller K, Maloney M, Perera N, Incekara K, Petit S, Ramachandran V, Grossman M, Valderrama A, Chochua S, McGee L, Metcalf B, Schrag S, Sosa L. 589. Late Onset Invasive Group B Streptococcal Disease Outbreak in a Neonatal Intensive Care Unit Identified Through Whole Genome Sequencing — Connecticut, 2020–2024. Open Forum Infectious Diseases 2025, 12: ofae631.184. PMCID: PMC11778314, DOI: 10.1093/ofid/ofae631.184.Peer-Reviewed Original ResearchConceptsNeonatal intensive care unitGroup B streptococciGroup B Streptococcus isolatesWhole-genome sequencingIntensive care unitLate-onset diseaseOutbreak-related casesSingle nucleotide polymorphismsColonized infantsCare unitColon screeningGroup B streptococcus colonizationActive Bacterial Core surveillance programIntegration of whole genome sequencingDepartment of Public HealthAssessment of infection preventionDays of lifeIPC gapsLOD casesNeonatal sepsisB streptococciReview of dataConnecticut Department of Public HealthOutbreak-relatedIllness onsetHousehold transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants
Baker J, Nakayama J, O’Hegarty M, McGowan A, Teran R, Bart S, Sosa L, Brockmeyer J, English K, Mosack K, Bhattacharyya S, Khubbar M, Yerkes N, Campos B, Paegle A, McGee J, Herrera R, Pearlowitz M, Williams T, Kirking H, Tate J. Household transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants. PLOS ONE 2025, 20: e0313680. PMID: 39787187, PMCID: PMC11717262, DOI: 10.1371/journal.pone.0313680.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPublic health jurisdictionsTransmission riskGeneralized Estimating EquationsHealth jurisdictionsSARS-CoV-2 transmissionSARS-CoV-2Household contactsIndex casePrevention strategiesRisk estimatesImpact SARS-CoV-2 transmissionConfidence intervalsSymptom statusMultivariate modelUS jurisdictionsSARS-CoV-2 DeltaEstimate differencesHousehold transmission rateOmicron variantSocial factorsSource of SARS-CoV-2 transmissionCOVID-19 vaccine dosesSARS-CoV-2 variantsRiskSymptomatic index cases
2024
Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears
Grossman M, Rankin D, Maloney M, Stanton R, Gable P, Stevens V, Ewing T, Saunders K, Kogut S, Nazarian E, Bhaurla S, Mephors J, Mongillo J, Stonehocker S, Prignano J, Valencia N, Charles A, McNamara K, Fritsch W, Ruelle S, Plucinski C, Sosa L, Ostrowsky B, Ham D, Walters M, Aguilar H, Alavi A, Balbuena R, Braut-Taormina J, Bruce H, Chambers W, Chen K, Clancy K, Cockrell M, Crayton K, Cyrus M, D'Angeli M, Diaz M, Dollete J, Eskenazi S, Fong L, Giardina R, Gogley J, Greendyke W, Hadman S, Houston H, Huck C, Istafanos P, Jean-Louis A, Jones D, Kratz M, Kwan T, La S, Lance S, Lasure M, Longo C, Machado M, McAllister G, McGarry S, McKay S, Miller D, Musk M, O'Yong K, Patel E, Pightling A, Rodriguez A, Rogers J, Romero H, Satyam M, Silverman M, Skolek G, Smith A, Stahl A, Torres L, Trivedi K, Wilmott N. Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears. Clinical Infectious Diseases 2024, 79: 6-14. PMID: 38315890, PMCID: PMC11259536, DOI: 10.1093/cid/ciae052.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCase-patientsCase-control studyDays of culture collectionCarbapenem-resistant Pseudomonas aeruginosaOver-the-counterArtificial tear useCarbapenemase-producing organismsDrug-resistant bacteriaCarbapenemase-producingSurveillance culturesPatient isolatesPreservative-freeClinical impactEye infectionsSpecimen sourceClinical culturesSequence typingIncreased oddsUnopened bottlesResistant bacteriaPost-acute care facilitiesCase statusBrand ABacterial contaminationCulture Collection
2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory Committee
2022
Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox — United States, May 17–September 24, 2022
Hennessee I, Shelus V, McArdle C, Wolf M, Schatzman S, Carpenter A, Minhaj F, Petras J, Cash-Goldwasser S, Maloney M, Sosa L, Jones S, Mangla A, Harold R, Beverley J, Saunders K, Adams J, Stanek D, Feldpausch A, Pavlick J, Cahill M, O’Dell V, Kim M, Alarcón J, Finn L, Goss M, Duwell M, Crum D, Williams T, Hansen K, Heddy M, Mallory K, McDermott D, Cuadera M, Adler E, Lee E, Shinall A, Thomas C, Ricketts E, Koonce T, Rynk D, Cogswell K, McLafferty M, Perella D, Stockdale C, Dell B, Roskosky M, White S, Davis K, Milleron R, Mackey S, Barringer L, Bruce H, Barrett D, D’Angeli M, Kocharian A, Klos R, Dawson P, Ellington S, Mayer O, Godfred-Cato S, Labuda S, McCormick D, McCollum A, Rao A, Salzer J, Kimball A, Gold J, Group C, Group C, Group C, Berumen R, Cosentino G, Getabecha S, Glaser C, Grosgebauer K, Harriman K, Haw M, Kamali A, Kath C, Kim E, Lewis L, Sachdev D, Salas M, Stainken C, Wadford D, Peters P, Vaidya A, Group C, Adkins S, Baird ;, Barrios L, Beeson A, Blackburn D, Borah B, Click E, Davidson W, Galang R, Hufstetler K, Hutchins H, Kourtis A, Miller M, Morris S, Olsen E, Roth N, Sims E, Chatham-Stephens K. Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox — United States, May 17–September 24, 2022. MMWR Morbidity And Mortality Weekly Report 2022, 71: 1407-1411. PMID: 36331124, PMCID: PMC9639439, DOI: 10.15585/mmwr.mm7144a4.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMale-to-male sexual contactPublic health priorityLt;18 yearsJurisdictional health departmentsSkin-to-skin contactChildren Aged 0Adolescents aged <Intensive care unit (ICU)-level careUnited StatesHealth priorityNon-HispanicHealth departmentsPrevention informationMonkeypox virusAged 0Prevent additional infectionsRisk factorsCareAdolescentsClinical featuresMonkeypox vaccineChildrenLt;18Monkeypox casesSexual contactSARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022
Baker J, Nakayama J, O’Hegarty M, McGowan A, Teran R, Bart S, Mosack K, Roberts N, Campos B, Paegle A, McGee J, Herrera R, English K, Barrios C, Davis A, Roloff C, Sosa L, Brockmeyer J, Page L, Bauer A, Weiner J, Khubbar M, Bhattacharyya S, Kirking H, Tate J. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022. MMWR Morbidity And Mortality Weekly Report 2022, 71: 341-346. PMID: 35238860, PMCID: PMC8893332, DOI: 10.15585/mmwr.mm7109e1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHousehold contactsIndex patientCOVID-19 primary seriesSARS-CoV-2Prevention strategiesCOVID-19 booster doseEffectiveness of prevention strategiesBooster dosePrimary seriesOmicron infectionPatientsOmicron transmissionHousehold transmissionVariant transmissionInfected personsHousehold settingsCOVID-19Cases of COVID-19InfectionOmicron
2020
Treatment Guidelines for Active Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis, and Latent Tuberculosis Infection
Sosa L, Friedman L. Treatment Guidelines for Active Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis, and Latent Tuberculosis Infection. 2020, 393-398. DOI: 10.1201/9781351249980-20.Peer-Reviewed Original ResearchConceptsExtensively Drug-Resistant TuberculosisInjectable agentsThree-drug regimensResistance to isoniazidMultidrug-resistant tuberculosisUnited States Food and Drug AdministrationLatent tuberculosis infectionDrug-resistant tuberculosisStates Food and Drug AdministrationDrug-sensitive tuberculosisFood and Drug AdministrationPulmonary tuberculosisSensitive to isoniazidDrug susceptibilityResistant TBTuberculosis infectionTreatment guidelinesDrug AdministrationRifampinWorld Health OrganizationTuberculosisIsoniazidRegimensMonthsTreatment
2019
Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women — United States, 2008 and 2016
McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, Bennett NM, Scahill M, Niccolai LM, Brackney M, Griffin MR, Pemmaraju M, Querec TD, Cleveland AA, Unger ER, Markowitz LE, Group H, Group H, Blankenship S, Allen S, Meek J, Higgins K, Hadler J, Sosa L, Saadeh K, Fink D, Silverberg M, Powell M, Allain S, Felsen C, Bogart R, Feiler M, Dahl R. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women — United States, 2008 and 2016. MMWR Morbidity And Mortality Weekly Report 2019, 68: 337-343. PMID: 30998672, PMCID: PMC6476057, DOI: 10.15585/mmwr.mm6815a1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigh-grade cervical lesionsRates of CIN2Human papillomavirusHPV vaccinationCervical lesionsHPV vaccine impactCervical cancer screeningCommon human papillomavirusAge 26 yearsAge-specific ratesHPV typesVaccine impactCervical cancerPrimary preventionCancer screeningCervical precancerCIN2Routine ageNumber of casesU.S. population dataVaccinationCancerWomenUnited StatesLesions
2017
Notes from the Field: Powassan Virus Disease in an Infant — Connecticut, 2016
Tutolo J, Staples J, Sosa L, Bennett N. Notes from the Field: Powassan Virus Disease in an Infant — Connecticut, 2016. MMWR Morbidity And Mortality Weekly Report 2017, 66: 408-409. PMID: 28426641, PMCID: PMC5687186, DOI: 10.15585/mmwr.mm6615a3.Peer-Reviewed Original ResearchCitationsAltmetric
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Mailing Address
Epidemiology of Microbial Diseases
410 Capitol Avenue MS #11 TUB
Hartford, CT 06134
United States